Effects of CYP2C19 variants on the metabolism of tapentadol in vitro

被引:1
|
作者
Xu, Ren-ai [1 ]
Fang, Ping [2 ]
Ye, Zhize [3 ]
Han, Mingming [3 ]
Cai, Jian-Ping [4 ]
Hu, Guo-Xin [3 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China
[4] Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Gerontol,Natl Hlth Commiss, Key Lab Geriatr,Beijing Inst Geriatr,Inst Geriatr, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
Cytochrome P450; Drug metabolism; Genetic polymorphism; Tapentadol; FUNCTIONAL-CHARACTERIZATION; GENETIC-POLYMORPHISM; ALLELIC VARIANTS; PHARMACOLOGY; POPULATION; TRAMADOL; ENZYMES; 2C19;
D O I
10.22038/IJBMS.2022.56996.12710
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective(s): This study aims to evaluate the catalytic activities of 31 CYP2C19 alleles and their effects on the metabolism of tapentadol in vitro. Materials and Methods: Insect microsomes expressing the CYP2C19 alleles were incubated with 50- 1250 mu M tapentadol for 40 min at 37 degrees C and terminated by cooling to -80 degrees C, immediately. Tapentadol and N-desmethyl tapentadol were analyzed by a UPLC-MS/MS system. The kinetic parameters Km, Vmax, and intrinsic clearance (Vmax/Km) of N-desmethyl tapentadol were determined. Results: As a result, the intrinsic clearance (Vmax/Km) values of most variants were significantly altered, while CYP2C19.3 and 35FS had no detectable enzyme activity. Only one variant, N277K, showed no significant difference from CYP2C19.1B. Two variants CYP2C19.29 and L16F displayed markedly increased intrinsic clearance values of 302.22% and 199.97%, respectively; whereas 24 variants exhibited significantly decreased relative clearance ranging from 0.32% to 79.15% of CYP2C19.1B. Especially, CYP2C19.2G, 2H, R124Q, and R261W exhibited a drastic decrease in clearance (>80%) compared with wild-type CYP2C19.1B. Conclusion: As the first study of all aforementioned alleles for tapentadol metabolism, the comprehensive data in vitro may provide novel insights into the allele-specific and substrate-specific activity of CYP2C19.
引用
收藏
页码:659 / 663
页数:5
相关论文
共 50 条
  • [41] Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro:: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism
    Shon, JH
    Yoon, YR
    Kim, MJ
    Kim, KA
    Lim, YC
    Liu, KH
    Shin, DH
    Lee, CH
    Cha, IJ
    Shin, JG
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 552 - 563
  • [42] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Zalloum, Imad
    Hakooz, Nancy
    Arafat, Tawfiq
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (04) : 4195 - 4200
  • [43] The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19☆2 genotyping
    Langaee, Taimour Y.
    Zhu, Hao-Jie
    Wang, Xinwen
    El Rouby, Nihal
    Markowitz, John S.
    Goldstein, Joyce A.
    Johnson, Julie A.
    PHARMACOGENETICS AND GENOMICS, 2014, 24 (08): : 381 - 386
  • [44] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Imad Zalloum
    Nancy Hakooz
    Tawfiq Arafat
    Molecular Biology Reports, 2012, 39 : 4195 - 4200
  • [45] Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin
    Ibeanu, GC
    Goldstein, JA
    Meyer, U
    Benhamou, S
    Bouchardy, C
    Dayer, P
    Ghanayem, BI
    Blaisdell, J
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 286 (03): : 1490 - 1495
  • [46] CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset
    Per Damkier
    Anders Kjærsgaard
    Kimberly A. Barker
    Deidre Cronin-Fenton
    Anatasha Crawford
    Ylva Hellberg
    Emilius A. M. Janssen
    Carl Langefeld
    Thomas P. Ahern
    Timothy L. Lash
    Scientific Reports, 7
  • [47] Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans
    Bottiger, Y
    Dostert, P
    Benedetti, MS
    Bani, M
    Fiorentini, F
    Casati, M
    Poggesti, I
    Alm, C
    Alvan, G
    Bertilsson, L
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (06) : 707 - 711
  • [48] CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset
    Damkier, Per
    Kjaersgaard, Anders
    Barker, Kimberly A.
    Cronin-Fenton, Deidre
    Crawford, Anatasha
    Hellberg, Ylva
    Janssen, Emilius A. M.
    Langefeld, Carl
    Ahern, Thomas P.
    Lash, Timothy L.
    SCIENTIFIC REPORTS, 2017, 7
  • [49] CYP2C19 and CYP3A4 gene variants and schizophrenia in Armenian patients
    Butenko, E. V.
    Mamedov, R. F. O.
    Ghazaryan, H. K.
    Zakharyan, R. V.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 269 - 270
  • [50] Metabolism disposition of lansoprazole in relation to the CYP2C19 phenotype status
    fu, liangqing
    wu, dezheng
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 224 - 224